That $930M drug Alexion bought to pair with Soliris, Ultomiris? AstraZeneca says it just aced a PhIII test
Back in 2019, Alexion paid $930 million to snap up Achillion and danicopan, its promising companion drug to Soliris. Three years later, Alexion itself became a subsidiary of AstraZeneca — which is taking the honors Friday morning to announce an interim Phase III success.
The drug met its primary endpoint of change in hemoglobin among patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis, when given on top of either Soliris or the follow-on Ultomiris.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.